Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis

Ankara University

Status: Unknown

Conditions: Neonatal Sepsis

Study type: Observational

Funder types: Other

Identifiers

NCT01294865

Ankara University-02

Ankara University (Other Grant/Funding Number)

Details and patient eligibility

About

The purpose of the study is to investigate the plasma levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) at the diagnosis and after treatment of sepsis, and to determine whether it has a diagnostic and prognostic value in late-onset neonatal sepsis.

Full description

Infection is a leading cause of neonatal morbidity and mortality worldwide. The clinical presentation of neonatal infection is subtle and nonspecific. Microbiologic cultures of clinical specimens, the gold standard for diagnosis, have low sensitivity and are not available in time to influence initial therapy. Therefore, reliable and rapid in vitro tests are needed for early diagnosis and management of infection in neonates. suPAR, secreted from the cells (neutrophils, lymphocytes, macrophages, endothelial cells) has recently been reported to be a potential biomarker for several infection diseases. The levels of suPAR have not been studied in newborn infants yet.

Enrollment: 120 estimated patients

Sex: All

Ages: 4 days to 1 month old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Infants with late-onset neonatal sepsis

Exclusion criteria

• Infants without parents' consent

Trial design

120 participants in 2 patient groups

septic

Description:

Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.

non-septic

Description:

Infants without any clinical or hematological septic signs. Blood samples will be taken only once.